Background/Objectives:Hyperthermic intraperitoneal chemotherapy (HIPEC) was revealed as a promising adjunct to cytoreductive surgery (CRS) in the treatment of advanced epithelial ovarian cancer (EOC). This review evaluated the impact HIPEC had on survival outcomes, recurrence patterns and safety in patients that underwent HIPEC in conjunction with interval and secondary CRS for advanced and recurrent ovarian cancer.Methods:A thorough search was conducted using PubMed, Scopus, Cochrane Library, and Google Scholar to identify relevant studies published until 1 January 2025. The studies were assessed for survival outcomes, recurrence patterns, safety, and quality of life. The risk of bias was evaluated using the ROB 2 tool for randomized and ROBINS-I for non-randomized articles. The results are presented narratively, highlighting key findings, comparing results and assessing inconsistencies and limitations.Results:HIPEC demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS), particularly in cases with optimal cytoreduction (CC-0/CC-1). The recurrence patterns showed a reduction in peritoneal dissemination with HIPEC, although extraperitoneal recurrences were reported in some cases. Most studies reported comparable morbidity rates between HIPEC and non-HIPEC groups, with acceptable safety profiles. The variability in the HIPEC protocols and the limited quality-of-life and cost-effectiveness data were noteworthy limitations.Conclusions:HIPEC, when performed during interval or secondary CRS, offers survival benefits and can modify recurrence patterns in advanced EOC, although challenges related to protocol standardization, patient selection, and long-term outcomes persist. Future research should focus on multicenter trials with uniform protocols, long follow-up periods and patient-centered outcomes to further validate the role of HIPEC in clinical practice.
背景/目的：腹腔热灌注化疗（HIPEC）已被证实是细胞减灭术（CRS）治疗晚期上皮性卵巢癌（EOC）的一种有前景的辅助手段。本综述评估了HIPEC对接受间歇性或二次CRS联合HIPEC治疗的晚期及复发性卵巢癌患者的生存结局、复发模式及安全性的影响。方法：通过PubMed、Scopus、Cochrane Library和Google Scholar数据库进行全面检索，筛选截至2025年1月1日发表的相关研究。评估内容包括生存结局、复发模式、安全性和生活质量。采用ROB 2工具评估随机研究的偏倚风险，采用ROBINS-I评估非随机研究的偏倚风险。结果以叙述性方式呈现，重点突出关键发现、比较结果并评估不一致性和局限性。结果：HIPEC显著改善了无进展生存期（PFS）和总生存期（OS），尤其是在达到理想细胞减灭（CC-0/CC-1）的病例中。复发模式显示HIPEC减少了腹膜播散，但部分病例报告了腹膜外复发。多数研究报道HIPEC组与非HIPEC组的并发症发生率相当，安全性可接受。HIPEC方案存在差异，以及生活质量和成本效益数据有限是值得注意的局限性。结论：在间歇性或二次CRS期间实施HIPEC可为晚期EOC患者带来生存获益，并可能改变复发模式，但方案标准化、患者选择和长期结局方面仍存在挑战。未来研究应侧重于采用统一方案、长期随访和以患者为中心结局的多中心试验，以进一步验证HIPEC在临床实践中的作用。
肿瘤(癌症)患者之家